Alpha radionuclide-chelated radioimmunotherapy promoters enable local radiotherapy/chemodynamic therapy to discourage cancer progression

Alpha radionuclide-chelated radioimmunotherapy promoters enable local radiotherapy/chemodynamic therapy to discourage cancer progression

Abstract Background Astatine-211 is an α-emitter with high-energy α-ray and high cytotoxicity for cancer cells. However, the targeted alpha therapy (TAT) also suffers from insufficient systematic immune activation, resulting in tumor metastasis and relapse. Combined immune checkpoint blockade (ICB)...

Full description

Bibliographic Details
Main Authors: Jiajia Zhang, Feize Li, Yuzhen Yin, Ning Liu, Mengqin Zhu, Han Zhang, Weihao Liu, Mengdie Yang, Shanshan Qin, Xin Fan, Yuanyou Yang, Kun Zhang, Fei Yu
Format: Article
Language:English
Published: American Association for the Advancement of Science (AAAS) 2022-09-01
Series:Biomaterials Research
Subjects:
Targeted alpha therapy
Immune activation
Chemodynamic therapy
Immune checkpoint blockade
Tumor relapse inhibition
Online Access:https://doi.org/10.1186/s40824-022-00290-6

Internet

https://doi.org/10.1186/s40824-022-00290-6

Similar Items